Cell-Free RNA Analysis Market (2026 - 2033)

Cell-Free RNA Analysis Market Summary

The global cell-free RNA analysis market size was valued at USD 43.3 million in 2025 and is projected to grow from USD 49.5 million in 2026 to USD 131.6 million by 2033, at a CAGR of 15.0% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 39.2% in 2025. The industry is driven by increasing adoption of cfRNA analysis for liquid biopsy, biomarker discovery, precision medicine, disease monitoring, and molecular diagnostics, along with advancements in sequencing and RNA analysis technologies.

Market Dynamics

The industry is witnessing strong growth, supported by increasing research activities in transcriptomics, growing applications in biomarker discovery and disease research, and rising adoption of RNA sequencing and digital PCR technologies. Expanding investments in molecular diagnostics, precision medicine, and translational research, coupled with improvements in cfRNA extraction, sequencing, and bioinformatics workflows, are further contributing to market expansion. In addition, increasing integration of multi-omics and artificial intelligence with cfRNA analysis is expected to create new opportunities for market growth over the forecast period.

Market Concentration & Characteristics

The industry is characterized by a high degree of innovation, driven by the development of sensitive cfRNA extraction, sequencing, amplification, and bioinformatics technologies. Companies are increasingly focusing on improving the recovery of low-abundance cfRNA and enabling comprehensive profiling from limited biological samples. For instance, in April 2026, Beckman Coulter Life Sciences expanded its Apostle MiniMax portfolio to include cfRNA and total cfNA isolation kits, supporting small RNA profiling, rare mutation detection, and multimodal analysis from liquid biopsy samples.

“We are seeing interest in cfRNA/cfNA extractions from labs that have been using cfDNA analyses. This follows a trend that we’ve previously experienced with FFPE samples in tumor characterization, where it has now become standard to analyze RNA and DNA from the same sample.”

- Milan Dieris, Field Application Specialist, Beckman Coulter Life Sciences

The industry is witnessing a moderate level of mergers and acquisitions, with strategic collaborations playing an important role in expanding research applications and strengthening technology capabilities. Companies are increasingly partnering with research institutions and biotechnology firms to explore cfRNA in disease mechanisms and biomarker discovery. For instance, in April 2026, Resolve Therapeutics and Institut Pasteur de Montevideo entered into a collaboration to use REJOIN-seq to identify cfRNA molecules associated with inflammatory pathways in autoimmune diseases, expanding the application of cfRNA analysis beyond conventional oncology-focused research.

The industry is influenced by regulatory requirements for molecular diagnostic tests, particularly those related to analytical validity, clinical performance, laboratory quality, and biomarker reproducibility. Regulatory expectations for cfRNA-based assays can increase the need for standardized sample handling, assay validation, and performance assessment, encouraging manufacturers to strengthen quality-control and validation processes.

The industry has witnessed moderate product expansion, supported by the introduction of dedicated cfRNA extraction, sequencing, and analysis solutions. Companies are broadening their portfolios to improve the recovery and characterization of low-abundance cfRNA and support downstream applications such as biomarker discovery, liquid biopsy, and molecular diagnostics. This expansion is strengthening the availability of specialized tools and workflows for research and clinical applications.

The industry is witnessing a moderate to high regional expansion, driven by increasing investments in genomics infrastructure, precision medicine, and molecular diagnostics across emerging markets. Expanding sequencing capabilities, research funding, and adoption of liquid biopsy technologies are creating opportunities for manufacturers to establish distribution networks and research collaborations are further strengthening regional market growth.

Analyst Perspective

The industry is driven by the increasing use of cell-free RNA biomarkers in non-invasive diagnostics, liquid biopsy, prenatal screening, and disease monitoring. Growing interest in early disease detection and personalized medicine is accelerating demand for sensitive RNA analysis technologies, while advancements in sequencing, digital PCR, and RNA extraction workflows are improving analytical sensitivity and accuracy. Increasing research into circulating RNA biomarkers and expanding clinical applications are expected to support long-term market growth, encouraging market participants to focus on innovative, scalable, and high-throughput analysis solutions.

Product & Service Insights

The reagents & kits segment accounted for the largest revenue share, over 37.3% in 2025, driven by their extensive use in cfRNA extraction, purification, library preparation, and downstream molecular analysis. These products enable efficient recovery and characterization of low-abundance cfRNA from biofluids, supporting applications such as liquid biopsy, biomarker discovery, disease monitoring, and transcriptomic research. Increasing adoption of sequencing-based workflows and demand for standardized sample preparation solutions are further supporting segment growth.

The analysis & testing services segment is expected to register the fastest CAGR over the forecast period, driven by increasing demand for specialized cfRNA sequencing, bioinformatics, and data interpretation services. The growing complexity of cfRNA datasets and expanding applications in liquid biopsy and biomarker discovery are encouraging greater use of outsourced analytical workflows. For instance, in January 2025, Flomics Biotech reported results demonstrating the use of cfRNA, next-generation sequencing, and AI-driven bioinformatics for multicancer early detection, highlighting the expanding application of specialized cfRNA analysis services.

Technology Insights

The RNA sequencing (RNA-seq/NGS) segment dominated the market with a share of 45.9% in 2025, owing to its ability to provide comprehensive transcriptomic profiling from limited biofluid samples. Increasing demand for sensitive detection of low-abundance RNA species and the application of sequencing in liquid biopsy and biomarker discovery further supported segment adoption. According to an article published in Nature in April 2025, researchers developed RARE-seq, an ultrasensitive sequencing-based method for cfRNA analysis that demonstrated approximately 50-fold higher sensitivity for detecting tumor-derived cfRNA than conventional whole-transcriptome RNA sequencing, highlighting the growing importance of advanced sequencing approaches in cfRNA analysis.

The digital PCR (dPCR) segment is expected to register the fastest CAGR over the forecast period, driven by the increasing adoption of dPCR for the highly sensitive and precise detection and quantification of low-abundance cell-free RNA (cfRNA) biomarkers. Its ability to provide absolute quantification without standard curves, along with improved accuracy in detecting rare molecular targets, is expected to support its growing use in liquid biopsy, cancer research, prenatal testing, and other molecular diagnostic applications.

Application Insights

The oncology segment dominated the market with a share of 36.3% in 2025, driven by the growing application of cfRNA as a minimally invasive biomarker for early cancer detection, molecular subtyping, treatment-response monitoring, and disease progression assessment. The ability of cfRNA to capture gene-expression and other transcriptomic changes complements DNA-based liquid biopsy approaches, further increasing its relevance in precision oncology.

The cardiovascular & metabolic disorders segment is expected to register the fastest CAGR over the forecast period, driven by the increasing prevalence of cardiovascular and metabolic diseases and the growing adoption of cell-free RNA analysis for the identification of disease-associated biomarkers. The expanding use of cfRNA for early disease detection, risk assessment, disease monitoring, and personalized therapeutic strategies is expected to further support segment growth.

End-use Insights

The academic & research institutes segment dominated the market with a share of 29.0% in 2025, driven by the increasing use of cell-free RNA analysis in biomarker discovery, disease mechanism studies, and translational research. Growing investments in genomics and multi-omics research, coupled with the expanding adoption of liquid biopsy-based approaches, have further supported the demand for cfRNA analysis technologies across academic and research settings.

The diagnostic laboratories segment is projected to witness the fastest CAGR, driven by the increasing adoption of cell-free RNA analysis for liquid biopsy testing, early disease detection, and precision diagnostics. Growing demand for non-invasive diagnostic solutions, expanding clinical validation of cfRNA biomarkers, and the rising integration of advanced molecular testing workflows are expected to further accelerate segment growth.

Regional Insights

The North America cell-free RNA analysis industry accounted for the largest revenue share of 39.2% in 2025, supported by advanced genomics infrastructure, strong biomedical research activity, and increasing investment in liquid biopsy technologies. According to an article published by NIH in April 2025, researchers published an ultrasensitive cfRNA detection method capable of identifying rare RNA molecules in blood, demonstrating potential applications in cancer detection and disease monitoring and strengthening the region’s cfRNA research ecosystem.

U.S. Cell-free RNA Analysis Market Trends

The cell-free RNA analysis industry in the U.S. is expected to grow over the forecast period, supported by increasing investment in cfRNA-based diagnostics and the development of advanced analytical platforms. For instance, in December 2025, Genomic Testing Cooperative announced 12 presentations at the American Society of Hematology Annual Meeting featuring proprietary approaches involving cfRNA analytics, AI-based prediction models, and transcriptomic signatures, highlighting expanding commercial interest in cfRNA applications.

Europe Cell-free RNA Analysis Market Trends

The cell-free RNA analysis market in Europe was identified as a lucrative region in this industry, driven by expanding precision medicine research and increasing interest in non-invasive molecular biomarkers. The region's established genomics ecosystem and increasing integration of transcriptomic technologies into clinical research are supporting the development of cfRNA-based applications across oncology, reproductive health, and disease monitoring.

The UK cell-free RNA analysis market is supported by strong biomedical research capabilities and increasing adoption of transcriptomics in precision medicine. Growing collaboration between academic institutions and healthcare organizations is accelerating the development of non-invasive cfRNA-based diagnostics and pregnancy monitoring solutions. For instance, in July 2025, researchers at the University of Cambridge demonstrated that sequencing cell-free RNA from maternal blood could predict pregnancy complications, including preeclampsia and fetal growth restriction, highlighting the expanding clinical potential of cfRNA analysis in the UK.

The cell-free RNA analysis market in Germany is anticipated to grow significantly over the forecast period, supported by its established biotechnology and diagnostics ecosystem, advanced sequencing infrastructure, and strong investment in molecular research. Increasing adoption of liquid biopsy, transcriptomics, and precision medicine is expected to expand the use of cfRNA analysis across oncology, disease monitoring, and biomarker discovery, supporting market growth over the forecast period.

Asia Pacific Cell-free RNA Analysis Market Trends

The cell-free RNA analysis market inAsia-Pacific is expected to grow at the fastest CAGR of 16.9% during the forecast period, supported by expanding genomics capabilities, increasing research investments, and growing adoption of advanced molecular analysis technologies. For instance, in December 2025, researchers from Harbin Institute of Technology and other Chinese institutions developed cfPeak, a statistical and machine-learning method for identifying fragmented cfRNA signals. The approach demonstrated potential for cancer detection and classification, highlighting the region’s growing capabilities in advanced cfRNA analysis and liquid biopsy research.

The China cell-free RNA analysis market is emerging as a significant market, supported by expanding precision medicine capabilities and advanced sequencing research. According to an article published by NIH in March 2025, researchers from South China University of Technology and BGI Research reported a wide-spectrum plasma cfRNA profiling approach capable of simultaneously characterizing mRNA, miRNA, lncRNA, tRNA, and mitochondrial RNA, demonstrating the country's growing capabilities in comprehensive cfRNA analysis.

The cell-free RNA analysis market in Japan is witnessing rapid growth, supported by advanced molecular diagnostics capabilities and growing investment in precision oncology. Increasing use of circulating RNA biomarkers for cancer characterization and treatment monitoring is creating opportunities for cfRNA analysis platforms, particularly in oncology-focused research and clinical applications.

Latin America Cell-Free RNA Analysis Market Trends

The cell-free RNA analysis market inLatin America is expected to grow steadily, supported by improving molecular diagnostic infrastructure and increasing participation in genomic research. Growing research collaborations and adoption of liquid biopsy technologies are creating opportunities for cfRNA-based biomarker development and clinical research across major regional markets.

MEA Cell-Free RNA Analysis Market Trends

The cell-free RNA analysis industry in the Middle East & Africa is anticipated to witness gradual growth, as molecular diagnostics infrastructure and genomic research capabilities expand. Increasing interest in infectious-disease biomarkers, precision medicine, and non-invasive testing is expected to create opportunities for cfRNA analysis technologies, particularly through collaborations with international biotechnology and research organizations.

Key Cell-free RNA Analysis Companies Insights

Several well-established companies operate in the cell-free RNA analysis market, driven by their portfolios of cfRNA extraction and purification kits, sequencing platforms, molecular analysis technologies, and research reagents. Leading players maintain a strong market presence through continuous product development, technological advancements, and strategic initiatives focused on cfRNA isolation, sequencing, biomarker analysis, and liquid biopsy applications.

Key Cell-free RNA Analysis Companies:

The following key companies have been profiled for this study on the ell-free RNA analysis market.

• QIAGEN

• Thermo Fisher Scientific Inc.

• Norgen Biotek Corp.

• Zymo Research Corporation

• New England Biolabs

• Illumina, Inc.

• Revvity

• Beckman Coulter Life Sciences

• PlexBio Co., Ltd.

• Geneaid Biotech Ltd.

• Bio-Rad Laboratories, Inc.

• nRichDX

Competitive Benchmarking

Recent Developments:

• In August 2026, New England Biolabs launched the Monarch Mag Cell-free RNA Extraction Kit for isolating low-abundance cfRNA from biofluids, supporting downstream sequencing, small RNA profiling, and amplification workflows for comprehensive cell-free nucleic acid analysis.

"While cfDNA has been the standard nucleic acid analyte in liquid biopsies, cfRNA carries information cfDNA cannot: which tissue a signal came from, and how pathology is changing over time."

- Anagha Kadam, Applications and Product Development Scientist II at NEB

• In January 2026, nRichDX and Hamilton collaborated to integrate automated liquid biopsy sample preparation with nucleic acid enrichment technologies, aiming to improve the recovery and processing of circulating nucleic acids. The collaboration supported automated workflows relevant to downstream cfRNA analysis and other molecular testing applications.

Cell-free RNA Analysis Market Report Scope

Global Cell-free RNA Analysis Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell-free RNA analysis market report on the basis of product & service, technology, application, end-use, and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Reagents & Kits

  • Instruments & Systems

  • Consumables

  • Analysis & Testing Services

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • RNA Sequencing (RNA-seq/NGS)

  • Digital PCR (dPCR)

  • RT-qPCR / qPCR

  • Microarray Analysis

  • Other Technologies

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Prenatal Screening & Maternal Health

  • Transplant Monitoring

  • Infectious Disease

  • Neurological Disorders

  • Cardiovascular & Metabolic Disorders

  • Research & Drug Development

  • Other Applications

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Hospitals & Clinics

  • Diagnostic Laboratories

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The cell-free RNA analysis market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each cell-free RNA analysis segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations